Skip to main content
SpringerLink
Log in

Respiratory Dysfunction

  • Chapter
Parkinson’s Disease and Nonmotor Dysfunction

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 967 Accesses

Abstract

Pulmonary complications remain a primary cause of morbidity and mortality in Parkinson’s disease (PD). Obstructive and restrictive airway deficits are related to disordered motor control of the respiratory musculature. Although this may sometimes lead to overt symptoms, such as stridor and respiratory failure, it more commonly results in silent aspiration and atelectasis, predisposing patients to pneumonia. Anti-Parkinson medications may produce pulmonary side effects (e.g., pleuropulmonary fibrosis associated with ergot-based dopamine agonists). Finally, motor fluctuations in patients with advanced PD may affect the respiratory system. Recognizing these pulmonary complications will assist the clinician in appropriately managing the disease and potentially reducing the impact of the abnormal respiratory system on the overall health of the patient with PD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parkinson J. An Essay on the Shaking Palsy. Sherwood, Nealy and Jones, London, 1817.

    Google Scholar 

  2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.

    Article  PubMed  CAS  Google Scholar 

  3. Mosewich RK, Rajput AH, Shuaib A, et al. Pulmonary embolism: an under-recognized yet frequent cause of death in Parkinsonism. Mov Disord 1994;9:350–352.

    Article  PubMed  CAS  Google Scholar 

  4. Nakashima K, Maeda M, Tabata M, et al. Prognosis of Parkinson’s Disease in Japan. Tottori University Parkinson’s Disease Epidemiology (TUPDE) Study Group Eur Neurol 1997;38:60–63.

    Google Scholar 

  5. Morgante L, Salemi G, Meneghini F, et al. Parkinson disease survival: a population-based study. Arch Neurol 2000;57:507–512.

    Article  PubMed  CAS  Google Scholar 

  6. Beyer MK, Herlofsen K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 2001;103:7–11.

    Article  PubMed  CAS  Google Scholar 

  7. Baker KK, Ramig LO, Luschei ES, Smith ME. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology 1998;51:1592–1598.

    PubMed  CAS  Google Scholar 

  8. Logemann JA, Fisher HB, Boshes B, Blonsky ER. Frequency and cooccurrence of vocal tract dysfunction in the speech of a large sample of Parkinson patients. J Speech Hear Disord 1978;43:47–57.

    PubMed  CAS  Google Scholar 

  9. Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phon Log 1994;46:9–17.

    Article  CAS  Google Scholar 

  10. Liotti M, Ramig LO, Vogel D, et al. Hypophonia in Parkinson’s disease. Neural correlates of voice treatment revealed by PET. Neurology 2003;60:432–440.

    PubMed  CAS  Google Scholar 

  11. Swart BJM, Willemse SC, Maassen BAM, Horstink MWIM. Improvement of voicing in patients with Parkinson’s disease by speech therapy. Neurology 2003;60:498–500.

    PubMed  Google Scholar 

  12. Berke GS, Gerratt B, Kreiman J, Jackson K. Treatment of Parkinson hypophonia with percutaneous collagen augmentation. Laryngoscope 1999;1098:1295–1299.

    Article  Google Scholar 

  13. Kim SH, Kearney JJ, Atkins JP. Percutaneous collagen augmentation for treatment of parkinsonian hypophonia. Otolaryngol Head Neck Surg 2002;126:653–656.

    Article  PubMed  Google Scholar 

  14. Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery 1995;37:680–687.

    Article  PubMed  CAS  Google Scholar 

  15. Lang AE, Duff J, Saint-Cyr JA, et al. Posteroventral medial pallidotomy in Parkinson’s disease. J Neurol 1999;246(Suppl 2):28–41.

    Article  Google Scholar 

  16. Okun MS, Stover NP, Subramanian T, et al. Complications of gamma knife surgery for Parkinson’s disease. Arch Neurol 2001;58:1995–2002.

    Article  PubMed  CAS  Google Scholar 

  17. Romito LM, Scerrati M, Contarin MF, et al. Long-term follow up of subthalamic nucleus stimulation in Parkinson’s disease. Neurology 2002;58:15.

    Google Scholar 

  18. Neu HC, Connolly JJ, Jr., Schwertley FW, et al. Obstructive respiratory dysfunction in parkinsonian patients. Am Rev Respir Dis 1967;95:33–47.

    PubMed  CAS  Google Scholar 

  19. Obenour WH, Stevens PM, Cohen AA, McCutchen JJ. The causes of abnormal pulmonary function in Parkinson’s disease. Am Rev Respir Dis 1972;105:382–387.

    PubMed  CAS  Google Scholar 

  20. Vincken WG, Gauthier SG, Dollfuss RE, et al. Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation. N Engl J Med 1984;311:438–442.

    Article  PubMed  CAS  Google Scholar 

  21. Hovestadt A, Bogaard JM, Meerwaldt JD, et al. Pulmonary function in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989;52:329–333.

    PubMed  CAS  Google Scholar 

  22. Read D, Young A. Stridor and Parkinsonism. Postgrad Med J 1983;59:520–521.

    PubMed  CAS  Google Scholar 

  23. Fink ME, Klebanoff LM, Lennihan L, Fahn S. Acute respiratory failure during drug manipulation in patients with Parkinson’s disease. Neurology 1989;39:348.

    Google Scholar 

  24. Riley DE, Grossman G, Martin L. Acute respiratory failure from dopamine agonist withdrawal. Neurology 1992;42:1843–1844.

    PubMed  CAS  Google Scholar 

  25. Easdown LJ, Tessler MJ, Minuk J. Upper airway involvement in Parkinson’s disease resulting in postoperative respiratory failure. Can J Anaesth 1995;42:344–347.

    Article  PubMed  CAS  Google Scholar 

  26. Langer H, Woolf CR. Changes in pulmonary function Parkinson’s syndrome after treatment with L-dopa. Am Rev Respir Dis 1971;104:440–442.

    PubMed  CAS  Google Scholar 

  27. de Bruin PF, de Bruin VM, Lees AJ, Pride NB. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson’s disease. Am Rev Respir Dis 1993;148:1576–1580.

    PubMed  Google Scholar 

  28. Herer B, Arnulf I, Housset B. Effects of levodopa on pulmonary function in Parkinson’s disease. Chest 2001;119:387–393.

    Article  PubMed  CAS  Google Scholar 

  29. Izquierdo-Alonso JL, Jimenez-Jimenez FJ, Cabrera-Valdivia F, Mansilla-Lesmes M. Airway dysfunction in patients with Parkinson’s disease. Lung 1994;172:47–55.

    Article  PubMed  CAS  Google Scholar 

  30. Sabate M, Gonzalez I, Ruperez F, Rodriguez M. Obstructive and restrictive pulmonary dysfunctions in Parkinson’s disease. J Neurol Sci 1996;138:114–119.

    Article  PubMed  CAS  Google Scholar 

  31. Pepper PV, Goldstein MK. Postoperative complications in Parkinson’s disease. J Am Geriatr Soc 1999;47:967–972.

    PubMed  CAS  Google Scholar 

  32. Fontana GA, Pantaleo T, Lavorini F, et al. Defective motor control of coughing in Parkinson’s disease. Am J Respir Crit Care Med 1998;158:458–464.

    PubMed  CAS  Google Scholar 

  33. Galvez-Jimenez N, Lang AE. Perioperative problems in Parkinson’s disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci 1996;23:198–203.

    PubMed  CAS  Google Scholar 

  34. Chester CS, Gottfried SB, Cameron DI, Strohl KP. Pathophysiological findings in a patient with Shy-Drager and alveolar hypoventilation syndromes. Chest 1988;94:212–214.

    Article  PubMed  CAS  Google Scholar 

  35. Apps MCP, Scheaff PC, Ingram DA, et al. Respiration and sleep in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1985;48:1240–1245.

    PubMed  CAS  Google Scholar 

  36. Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov Disord 2000;15:699–704.

    Article  PubMed  CAS  Google Scholar 

  37. Estenne M, Hubert M, De Troyer A. Respiratory-muscle involvement in Parkinson’s disease. N Engl J Med 1984;311:1516–1517.

    Article  PubMed  CAS  Google Scholar 

  38. Schwab RD, England AC, Peterson E. Akinesia, in Parkinson’s disease. Neurology 1959;9:65–72.

    PubMed  CAS  Google Scholar 

  39. Nugent CA, Harris HW, Cohn J, et al. Dyspnea as a symptom in Parkinson’s syndrome. Am Rev Tuberc 1958;78:682–691.

    PubMed  CAS  Google Scholar 

  40. Tzelepis GE, McCool FD, Friedman JH, Hoppin FG, Jr. Respiratory muscle dysfunction in Parkinson’s disease. Am Rev Respir Dis 1988;138:266–271.

    PubMed  CAS  Google Scholar 

  41. Sabate M, Rodriguez M, Mendez E, et al. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease. Arch Phys Med Rehabil 1996;77:29–34.

    Article  PubMed  CAS  Google Scholar 

  42. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30:613–616.

    Article  PubMed  CAS  Google Scholar 

  43. Geminiani G, Fetoni V, Genitrini S, et al. Cabergoline in Parkinson’s disease complicated by motor fluctuations. Mov Disord 1996;11:495–500.

    Article  PubMed  CAS  Google Scholar 

  44. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med 1988;148:2231–2236.

    Article  PubMed  CAS  Google Scholar 

  45. Todman DH, Oliver WA, Edwards RL. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson’s disease. Clin Exp Neurol 1990;27:79–82.

    PubMed  CAS  Google Scholar 

  46. LeWitt PA, Calne DB. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson’s disease. Lancet 1981;1:44–45.

    Google Scholar 

  47. Hillerdal G, Lee J, Blomkvist A, et al. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur Respir J 1997;10:2711–2715.

    Article  PubMed  CAS  Google Scholar 

  48. Weiner WJ, Goetz CG, Nausieda PA, Klawans HL. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978;88:327–331.

    PubMed  CAS  Google Scholar 

  49. Zupnick HM, Brown LK, Miller A, Moros DA. Respiratory dysfunction due to L-dopa therapy for Parkinsonism, diagnosis using serial pulmonary function tests and respiratory inductive plethysmography. Am J Med 1990;89:109–114.

    Article  PubMed  CAS  Google Scholar 

  50. Corbin DO, Williams AC. Stridor during dystonic phases of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1987;50:821–822.

    PubMed  CAS  Google Scholar 

  51. Hartman DE. Stridor during dystonia phases of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:161.

    PubMed  CAS  Google Scholar 

  52. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. “Panic attacks” in Parkinson’s disease. A long-term complication of levodopa therapy. Acta Neurol Scand 1993;87:14–18.

    Article  PubMed  CAS  Google Scholar 

  53. Stacy M. Pharmacotherapy for advanced Parkinson’s disease. Pharmacotherapy 2000;20:8S–16S.

    Article  PubMed  CAS  Google Scholar 

  54. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s Disease. Neurology 2002;59:408–413.

    PubMed  Google Scholar 

  55. Canning CG, Alison JA, Allen NE, Groeller H. Parkinson’s disease: an investigation of exercise capacity, respiratory function, and gait. Arch Phys Med Rehabil 1997;78:199–207.

    Article  PubMed  CAS  Google Scholar 

  56. Bergen JL, Toole T, Elliott RG, et al. Aerobic exercise intervention improves aerobic capacity and movement initiation in Parkinson’s disease patients. Neurorehabilitation 2002;17:161–168.

    PubMed  Google Scholar 

  57. Koseoglu F, Inan L, Ozel S, et al. The effects of a pulmonary rehabilitation program on pulmonary function tests and exercise tolerance in patients with Parkinson’s disease. Funct Neurol 1997;12:319–325.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Barrow Neurological Institute, Phoenix, AZ

    Holly A. Shill MD

Authors
  1. Holly A. Shill MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN

    Ronald F. Pfeiffer MD

  2. Department of Neurology, State University of New York, Downstate Medical Center, Brooklyn, NY

    Ivan Bodis-Wollner MD, DSc

  3. Department of Ophthalmology, State University of New York, Downstate Medical Center, Brooklyn, NY

    Ivan Bodis-Wollner MD, DSc

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Shill, H.A. (2005). Respiratory Dysfunction. In: Pfeiffer, R.F., Bodis-Wollner, I. (eds) Parkinson’s Disease and Nonmotor Dysfunction. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-859-5:173

Download citation

  • DOI: https://doi.org/10.1385/1-59259-859-5:173

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-316-9

  • Online ISBN: 978-1-59259-859-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation